Profile data is unavailable for this security.
About the company
Theracryf PLC, formerly Evgen Pharma plc, is a clinical-stage therapeutics company. The Company is engaged in developing a new generation of therapeutics in oncology and behavioral brain disorders. Its pipeline and lead compound SFX-01 is derived from its proprietary Sulforadex technology. Its Sulforadex technology synthesizes sulforaphane into an active, stable, and solid form pharmaceutical ingredient, unlocking its medical and commercial potential. SFX-01 is a complex of sulforaphane and alpha-cyclodextrin formulated as a stable tablet. The Company has a candidate orexin 1 antagonist at late preclinical stage targeting addictive behaviors. It also has a candidate molecule DAT inhibitor at late preclinical stage targeting fatigue and narcolepsy.
- Revenue in GBP (TTM)838.00k
- Net income in GBP-3.35m
- Incorporated2014
- Employees7.00
- LocationTheraCryf PLCSuite 24G13 - Block 24 Alderley ParkCongleton Road, Nether AlderleyNETHERTON SK10 4TGUnited KingdomGBR
- Phone+44 162 531 5090
- Websitehttps://evgen.com/
Mergers & acquisitions
Acquired company | TCF:LSE since announced | Transaction value |
---|---|---|
Chronos Therapeutics Ltd | -21.05% | 4.33m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Nuformix PLC | 0.00 | -436.95k | 1.43m | 2.00 | -- | 0.3105 | -- | -- | -0.0006 | -0.0006 | 0.00 | 0.0056 | 0.00 | -- | -- | -- | -9.50 | -- | -9.95 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- |
ReNeuron Group Plc | 249.00k | -5.07m | 1.93m | 34.00 | -- | 0.7966 | -- | 7.75 | -0.0888 | -0.0888 | 0.0044 | 0.0424 | 0.0246 | -- | 0.6442 | 7,323.53 | -50.10 | -43.12 | -101.09 | -58.50 | -- | -- | -2,037.35 | -714.73 | -- | -- | 0.1247 | -- | 31.51 | 65.26 | 44.18 | -- | -1.31 | -- |
N4 Pharma PLC | 1.95k | -1.28m | 2.15m | 5.00 | -- | 1.91 | -- | 1,102.69 | -0.0053 | -0.0053 | 0.00001 | 0.0042 | 0.0011 | -- | 0.009 | 390.00 | -74.20 | -57.05 | -79.41 | -61.13 | -- | -- | -65,475.90 | -309,312.80 | -- | -- | 0.00 | -- | -- | -51.52 | -24.05 | -- | -- | -- |
Hellenic Dynamics PLC | -100.00bn | -100.00bn | 2.96m | 25.00 | -- | 3.73 | -- | -- | -- | -- | -- | 0.006 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.3029 | -- | -- | -- | -- | -- | -- | -- |
Fusion Antibodies PLC | 1.58m | -2.84m | 3.19m | 50.00 | -- | 1.37 | -- | 2.02 | -0.0861 | -0.0861 | 0.0436 | 0.0245 | 0.5229 | 3.15 | 1.88 | 31,580.00 | -93.94 | -31.29 | -130.56 | -37.72 | -7.41 | 42.58 | -179.67 | -48.25 | 2.32 | -- | 0.0313 | -- | -39.55 | 1.52 | -116.33 | -- | -23.83 | -- |
TheraCryf PLC | 838.00k | -3.35m | 3.21m | 7.00 | -- | 0.5239 | -- | 3.82 | -0.0122 | -0.0122 | 0.0031 | 0.0143 | 0.1406 | -- | 1.81 | 119,714.30 | -56.25 | -42.37 | -60.57 | -46.32 | -- | -- | -400.12 | -2,324.84 | -- | -- | 0.00 | -- | -- | -- | -48.10 | -- | -32.24 | -- |
Oxford Cannabinoid Tchnlgs Hldngs PLC | 0.00 | -4.24m | 3.76m | 7.00 | -- | 1.70 | -- | -- | -0.0044 | -0.0044 | 0.00 | 0.002 | 0.00 | -- | -- | 0.00 | -82.98 | -56.41 | -104.70 | -66.13 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -26.16 | -- | -- | -- |
IXICO PLC | 6.67m | -1.18m | 3.93m | 89.00 | -- | 0.3436 | -- | 0.5894 | -0.0244 | -0.0244 | 0.138 | 0.2364 | 0.4822 | -- | 2.82 | 74,887.64 | -8.52 | 4.35 | -9.57 | 5.33 | 49.06 | 62.09 | -17.67 | 6.61 | -- | -- | 0.0327 | 0.00 | -22.89 | 4.32 | -214.15 | -- | 92.12 | -- |
ValiRx Plc | 0.00 | -2.41m | 4.30m | 8.00 | -- | 0.791 | -- | -- | -0.0256 | -0.0256 | 0.00 | 0.0411 | 0.00 | -- | -- | 0.00 | -69.67 | -58.85 | -69.21 | -68.96 | -- | -- | -- | -- | -- | -575.81 | 0.0072 | -- | -- | -- | -55.87 | -- | -- | -- |
BSF Enterprise PLC | 12.94k | -1.50m | 5.17m | 4.00 | -- | 1.06 | -- | 399.29 | -0.0159 | -0.0159 | 0.0001 | 0.047 | 0.0028 | 2.11 | 0.0837 | 3,235.00 | -32.30 | -- | -34.46 | -- | -451.16 | -- | -11,600.08 | -- | 8.16 | -154.86 | 0.0313 | -- | -- | -- | -61.40 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Rathbones Investment Management Ltd.as of 05 Apr 2024 | 25.79m | 9.38% |
Octopus Investments Ltd.as of 05 Apr 2024 | 21.88m | 7.96% |
Vulpes Investment Management Pte Ltd.as of 11 Apr 2024 | 20.55m | 7.48% |
AXA Investment Managers UK Ltd.as of 27 Dec 2023 | 13.40m | 4.88% |
Chelverton Asset Management Ltd.as of 05 Jun 2023 | 12.50m | 4.55% |
RAB Capital Ltd. (Investment Management)as of 05 Jun 2023 | 8.75m | 3.18% |
Hargreaves Lansdown Asset Management Ltd.as of 01 Jun 2023 | 7.77m | 2.83% |
Jarvis Investment Management Ltd.as of 01 Jun 2023 | 4.55m | 1.65% |
IG Markets Ltd.as of 01 Jun 2023 | 3.89m | 1.42% |
Rowan Dartington & Co. Ltd. (Broker)as of 01 Jun 2023 | 3.69m | 1.34% |